News
Sanders, 56, revealed he suffered a heart attack on Father’s Day in 2024 —an event he also discusses in the new Amgen/A&E ...
A systematic review of 63 cases found that pyoderma gangrenosum (PG) during pregnancy or postpartum was often misdiagnosed, ...
Amgen Inc. closed 13.40% below its 52-week high of $346.85, which the company achieved on July 25th.
The phase 3 FORTITUDE-101 trial, conducted with the support of Zai Lab, has been evaluating bemarituzumab plus mFOLFOX6 ...
A court battle between two of the nation’s largest biotechs is testing the legal limits of how far drugmakers can go in using ...
Monthly weight-loss shots on the horizon! Learn about new drugs like MariTide and why Black participation in clinical trials ...
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Italy’s Robin Foà, MD, an iconic European clinician-researcher, has been at forefront of hematology’s transformation for half ...
Cartesian's mRNA-based cell therapy offers a novel, outpatient approach for autoimmune diseases. Promising results, but Phase ...
The European Commission (EC) has approved Biocon Biologics’ biosimilars referencing Amgen’s bone disease therapy denosumab.
Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...
Leading companies, such as Incyte Corporation, TWi Biotechnology, Amgen, Pfizer, Arcutis Biotherapeutics, AnaptysBio, and others, are actively advancing promising drug candidates aimed at improving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results